vs
基华物流（CEVA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是基华物流的1.1倍（$35.5M vs $31.3M），基华物流净利率更高（-3.5% vs -304.2%，领先300.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 7.1%），基华物流自由现金流更多（$7.2M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 19.1%）
赛物流是一家全球物流与供应链企业，提供货运管理以及合约物流服务，2019年被达飞海运集团收购。收购完成后，达飞集团陆续将英格迈微商务生命周期服务、GEFCO等多家物流运输企业并入赛物流，助力其业务发展与规模扩张。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CEVA vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.1倍
$31.3M
营收增速更快
RXRX
高出674.7%
7.1%
净利率更高
CEVA
高出300.7%
-304.2%
自由现金流更多
CEVA
多$54.5M
$-47.3M
两年增速更快
RXRX
近两年复合增速
19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.3M | $35.5M |
| 净利润 | $-1.1M | $-108.1M |
| 毛利率 | 88.1% | 59.8% |
| 营业利润率 | -1.3% | -304.8% |
| 净利率 | -3.5% | -304.2% |
| 营收同比 | 7.1% | 681.7% |
| 净利润同比 | 36.8% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CEVARXRX
| Q4 25 | $31.3M | $35.5M | ||
| Q3 25 | $28.4M | $5.2M | ||
| Q2 25 | $25.7M | $19.2M | ||
| Q1 25 | $24.2M | $14.7M | ||
| Q4 24 | $29.2M | $4.5M | ||
| Q3 24 | $27.2M | $26.1M | ||
| Q2 24 | $28.4M | $14.4M | ||
| Q1 24 | $22.1M | $13.8M |
净利润CEVARXRX
| Q4 25 | $-1.1M | $-108.1M | ||
| Q3 25 | $-2.5M | $-162.3M | ||
| Q2 25 | $-3.7M | $-171.9M | ||
| Q1 25 | $-3.3M | $-202.5M | ||
| Q4 24 | $-1.7M | $-178.9M | ||
| Q3 24 | $-1.3M | $-95.8M | ||
| Q2 24 | $-291.0K | $-97.5M | ||
| Q1 24 | $-5.4M | $-91.4M |
毛利率CEVARXRX
| Q4 25 | 88.1% | 59.8% | ||
| Q3 25 | 88.0% | -183.8% | ||
| Q2 25 | 86.2% | -4.9% | ||
| Q1 25 | 85.6% | -48.0% | ||
| Q4 24 | 88.5% | -181.4% | ||
| Q3 24 | 85.4% | 53.7% | ||
| Q2 24 | 89.7% | 36.2% | ||
| Q1 24 | 88.7% | 19.1% |
营业利润率CEVARXRX
| Q4 25 | -1.3% | -304.8% | ||
| Q3 25 | -7.3% | -3327.6% | ||
| Q2 25 | -17.5% | -916.8% | ||
| Q1 25 | -18.1% | -1297.9% | ||
| Q4 24 | 0.3% | -4042.4% | ||
| Q3 24 | -9.6% | -377.1% | ||
| Q2 24 | -0.1% | -697.4% | ||
| Q1 24 | -22.5% | -698.4% |
净利率CEVARXRX
| Q4 25 | -3.5% | -304.2% | ||
| Q3 25 | -8.8% | -3135.3% | ||
| Q2 25 | -14.4% | -894.2% | ||
| Q1 25 | -13.7% | -1373.3% | ||
| Q4 24 | -5.9% | -3935.5% | ||
| Q3 24 | -4.8% | -367.5% | ||
| Q2 24 | -1.0% | -676.6% | ||
| Q1 24 | -24.7% | -662.4% |
每股收益（稀释后）CEVARXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.6M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $336.5M | $1.1B |
| 总资产 | $388.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CEVARXRX
| Q4 25 | $40.6M | $743.3M | ||
| Q3 25 | $17.3M | $659.8M | ||
| Q2 25 | $29.1M | $525.1M | ||
| Q1 25 | $18.8M | $500.5M | ||
| Q4 24 | $18.8M | $594.4M | ||
| Q3 24 | $13.2M | $427.6M | ||
| Q2 24 | $25.0M | $474.3M | ||
| Q1 24 | $21.6M | $296.3M |
总债务CEVARXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CEVARXRX
| Q4 25 | $336.5M | $1.1B | ||
| Q3 25 | $268.7M | $1.0B | ||
| Q2 25 | $265.9M | $919.1M | ||
| Q1 25 | $269.1M | $933.9M | ||
| Q4 24 | $266.6M | $1.0B | ||
| Q3 24 | $265.8M | $524.6M | ||
| Q2 24 | $263.8M | $584.4M | ||
| Q1 24 | $262.3M | $401.2M |
总资产CEVARXRX
| Q4 25 | $388.3M | $1.5B | ||
| Q3 25 | $306.0M | $1.4B | ||
| Q2 25 | $302.8M | $1.3B | ||
| Q1 25 | $310.0M | $1.3B | ||
| Q4 24 | $308.9M | $1.4B | ||
| Q3 24 | $304.9M | $726.5M | ||
| Q2 24 | $300.4M | $775.9M | ||
| Q1 24 | $301.4M | $557.8M |
负债/权益比CEVARXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $7.2M | $-47.3M |
| 自由现金流率自由现金流/营收 | 23.1% | -133.1% |
| 资本支出强度资本支出/营收 | 4.8% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-6.3M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CEVARXRX
| Q4 25 | $8.7M | $-46.1M | ||
| Q3 25 | $-5.9M | $-117.4M | ||
| Q2 25 | $1.2M | $-76.4M | ||
| Q1 25 | $-7.4M | $-132.0M | ||
| Q4 24 | $8.0M | $-115.4M | ||
| Q3 24 | $399.0K | $-59.2M | ||
| Q2 24 | $2.4M | $-82.2M | ||
| Q1 24 | $-7.3M | $-102.3M |
自由现金流CEVARXRX
| Q4 25 | $7.2M | $-47.3M | ||
| Q3 25 | $-6.3M | $-117.6M | ||
| Q2 25 | $492.0K | $-79.6M | ||
| Q1 25 | $-7.7M | $-133.8M | ||
| Q4 24 | $7.0M | $-116.7M | ||
| Q3 24 | $-15.0K | $-63.8M | ||
| Q2 24 | $1.8M | $-83.4M | ||
| Q1 24 | $-8.3M | $-109.0M |
自由现金流率CEVARXRX
| Q4 25 | 23.1% | -133.1% | ||
| Q3 25 | -22.1% | -2272.5% | ||
| Q2 25 | 1.9% | -413.9% | ||
| Q1 25 | -31.8% | -907.4% | ||
| Q4 24 | 24.0% | -2567.7% | ||
| Q3 24 | -0.1% | -244.6% | ||
| Q2 24 | 6.2% | -578.5% | ||
| Q1 24 | -37.4% | -789.9% |
资本支出强度CEVARXRX
| Q4 25 | 4.8% | 3.5% | ||
| Q3 25 | 1.5% | 4.7% | ||
| Q2 25 | 2.7% | 16.4% | ||
| Q1 25 | 1.3% | 12.4% | ||
| Q4 24 | 3.5% | 28.6% | ||
| Q3 24 | 1.5% | 17.5% | ||
| Q2 24 | 2.1% | 8.2% | ||
| Q1 24 | 4.1% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CEVA
| Transferred At Point In Time | $28.1M | 90% |
| Transferred Over Time | $3.2M | 10% |
RXRX
暂无分部数据
